Clinical trials
Completed Venous Thromboembolism trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
403 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 4 |
| 2001 | 3 |
| 2002 | 8 |
| 2003 | 2 |
| 2004 | 6 |
| 2005 | 7 |
| 2006 | 19 |
| 2007 | 15 |
| 2008 | 19 |
| 2009 | 24 |
| 2010 | 23 |
| 2011 | 17 |
| 2012 | 12 |
| 2013 | 19 |
| 2014 | 22 |
| 2015 | 26 |
| 2016 | 28 |
| 2017 | 27 |
| 2018 | 20 |
| 2019 | 11 |
| 2020 | 27 |
| 2021 | 25 |
| 2022 | 14 |
| 2023 | 4 |
| 2024 | 8 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 403 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bayer | 31 |
| Boehringer Ingelheim | 12 |
| Brigham and Women's Hospital | 11 |
| Ottawa Hospital Research Institute | 10 |
| Sanofi | 10 |
| Bristol-Myers Squibb | 9 |
| Daiichi Sankyo | 9 |
| University Hospital, Brest | 9 |
| University of Utah | 9 |
| McMaster University | 8 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Venous Thromboembolism | 403 |
| Venous Thrombosis | 119 |
| Pulmonary Embolism | 107 |
| Thrombosis | 37 |
| Thromboembolism | 28 |
| Neoplasms | 26 |
| Atrial Fibrillation | 21 |
| Hemorrhage | 17 |
| Cardiovascular Diseases | 12 |
| COVID-19 | 10 |
Trials
Showing 51 to 75 of 403. Each trial links to its page on Pharma Observatory.
303 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.